131. Antiviral NL-CVX1 Efficiently Blocks Infection of SARS-CoV-2 Viral Variants of Concern (VOC)

BACKGROUND: Using a computational approach, NL-CVX1 was developed by Neoleukin Therapeutics, Inc. to create a de novo protein that both blocks SARS-CoV-2 infection and is highly resilient to viral escape. In this study we evaluated the efficacy of NL-CVX1 against variants of the original SARS-CoV-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Wen, Walker, Matthew, Rebelo, Maria, Tang, Cong, Coelho, Ana R, Tatalick, Laurie, Riley, Marianne, Yu, Kevin, Blancas-Mejia, Luis M, Silva, Daniel-Adriano, Shoultz, David, Bernardes, Goncalo, Yen, Hui-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Oral Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644688/
http://dx.doi.org/10.1093/ofid/ofab466.131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644688/
http://dx.doi.org/10.1093/ofid/ofab466.131

Ejemplares similares